Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.82% of ...

On Wednesday, KeyCorp (KEY) stock saw a decline, ending the day at $17.3 which represents a decrease of $-0.34 or -1.93% from the prior close of $17.64. The stock opened at $17.5 and touched a low of ...

General Mills is releasing a run of the soup-flavored lozenges in limited quantities online for just a few Thursday mornings in January. Progresso is relying on a combination of exclusivity and ...

Associated British Foods Plc cut guidance for sales growth at its Primark discount fashion retailer, blaming weak UK consumer ...

Widespread support for a federal grade-crossing safety program emerged during a lengthy House subcommittee hearing, a session which also saw representatives of the railroad industry and rail labor lay ...

The Bridgeport Islanders are having a rough season, with the worst record in the Atlantic Division by 15 points and the only team in the American Hockey League (AHL) to have not cleared the 10-goal ...

Fintel reports that on January 23, 2025, Jefferies downgraded their outlook for Casella Waste Systems (NasdaqGS:CWST) from Buy to Hold. Analyst Price Forecast Suggests 9.73% Upside As of December 23, ...

The carrier predicted that it would generate an adjusted per-share loss of 20 cents to 40 cents for the current quarter, driven by relatively weak demand and high fuel prices.

U.S. initial jobless claims were higher last week, but the increase wasn’t as drastic as economist Thomas Simons of Jefferies had been expecting.

In addition to Trump, you can guarantee that virtually every tech company will mention AI revenue and spending. According to Jefferies analyst Brent Thill, Microsoft should report improved AI ...

As news trickled out about President Trump's announcement of a new $500 billion Stargate joint venture focused on artificial-intelligence infrastructure, some potential beneficiaries emerged.

Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...